This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Biotech Stocks Set to Beat Q3 Earnings Estimates
by Kinjel Shah
Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.
CannTrust (CTST) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
On CannTrust's (CTST) third-quarter earnings call, investor focus will be on the company's efforts to regain licenses for producing and selling cannabis.
Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) is expected to provide pipeline updates during the third-quarter earnings call.
Ascendis Pharma A/S (ASND) Upgraded to Buy: Here's Why
by Zacks Equity Research
Ascendis Pharma A/S (ASND) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ascendis Pivotal Growth Hormone Deficiency Study Data Positive
by Zacks Equity Research
Ascendis Pharma's (ASND) growth hormone deficiency candidate fares better than Pfizer's Genotropin in improving annual rate for increase in height in children.
What Makes Ascendis Pharma A/S (ASND) a New Buy Stock
by Zacks Equity Research
Ascendis Pharma A/S (ASND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Company News For Mar 5, 2019
by Zacks Equity Research
Companies in the news are; PLCE, BIIB, NITE, ASND and TAK
Ascendis Pharma Files IND for Hypoparathyroidism Candidate
by Zacks Equity Research
Ascendis Pharma (ASND) submits regulatory application to initiate a phase II study in the United States on its hypoparathyroidism therapy candidate, TransCon PTH.
All You Need to Know About Ascendis Pharma A/S (ASND) Rating Upgrade to Buy
by Zacks Equity Research
Ascendis Pharma A/S (ASND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Ascendis Pharma (ASND) Looks Good: Stock Adds 5.5% in Session
by Zacks Equity Research
Ascendis Pharma (ASND) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Ascendis (ASND) Catches Eye: Stock Gains 7.2% in Session
by Zacks Equity Research
Ascendis Pharma A/S (ASND) moved big last session, as its shares rose over 7% on the day.